ArticleAnnals of medicine and surgery (2012)2024

Revumenib (SNDX-5613): a promising menin inhibitor for the management of relapsed and refractory acute myeloid leukaemia (AML).

Harmla Hussain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.